Update on Dupilumab: HSE Management Supports Reimbursement

Less than a month from the last major development, Dupilumab receives green light for funding In a statement to the ISF and healthcare professionals this afternoon, the HSE notified patients that the Executive Management Team has supported reimbursement of Dupilumab under High Tech (Drugs Scheme) Arrangements. Availability of the new ‘first-in-class’ treatment will be “subject to […]